Post-Transplant Diabetes Mellitus
Post-transplant diabetes mellitus (PTDM)—previously called new-onset diabetes after transplantation (NODAT)—is a common and important complication, occurring in 5–20% of kidney transplant recipients. It increases the risk of cardiovascular disease, infections, and both patient and graft loss.
- Screening and Diagnosis
Regular screening is essential because early detection allows timely interventions that may reverse or improve the condition.
- Screening Tools:
Screening should include fasting plasma glucose, oral glucose tolerance testing (OGTT), and/or HbA1c.
Dipstick urinalysis for glucose should be performed at every visit. - Frequency:
High-intensity screening is recommended:
– Weekly for the first 4 weeks
– Every 3 months during the first year
– Annually thereafter
Screening is also required after starting or increasing corticosteroids, CNIs, or mTOR inhibitors. - Diagnostic Criteria (WHO/ADA):
– Fasting plasma glucose ≥126 mg/dL (7.0 mmol/L)
– Symptoms of hyperglycemia plus random glucose ≥200 mg/dL (11.1 mmol/L)
– 2-hour OGTT glucose ≥200 mg/dL - Timing of Diagnosis:
Transient hyperglycemia is common in the first month due to high-dose steroids.
A formal diagnosis of PTDM should generally be made once the patient is on stable maintenance immunosuppression—typically around 3 months post-transplant.
- Risk Factors
PTDM develops due to a combination of transplant-specific and general risk factors.
- Transplant-Specific Factors:
– Tacrolimus (higher risk than ciclosporin)
– Corticosteroids
– Acute rejection episodes
– mTOR inhibitors (sirolimus/everolimus) - General Patient Factors:
– Older age
– Obesity (BMI ≥30 kg/m²)
– Family history of type 2 diabetes
– Certain ethnicities (African American, Hispanic) - Pre-Existing Conditions:
– Hepatitis C infection
– Metabolic syndrome
- Management and Treatment Strategies
Management requires a multidisciplinary approach involving transplant and diabetes specialists.
- Immunosuppression Adjustment:
If PTDM develops, clinicians may consider:
– Minimizing or withdrawing corticosteroids
– Switching from tacrolimus to ciclosporin
These decisions must be balanced against the risk of acute rejection. - Glycemic Targets:
A maintenance HbA1c target of 7.0–7.5% is suggested.
Targets ≤6.0% should be avoided due to increased mortality and severe hypoglycemia risk in some populations. - Pharmacological Management:
Lifestyle modification, oral hypoglycemic agents, and insulin are all effective.
Some medications (e.g., metformin, acarbose) require dose adjustment or avoidance in patients with reduced kidney function. - Screening for Complications:
Patients with PTDM should undergo routine screening for diabetic complications, including retinal exams, foot care, and neuropathy assessments.
• Aspirin Prophylaxis:
Low-dose aspirin (65–100 mg/day) may be considered for primary cardiovascular prevention based on individual risk.
